Wunder Mobility Launches Its Own Sharing Ready E-Bike Co-developed With Yadea
29.10.2021 09:30:00 EEST | Business Wire | Press release
Wunder Mobility, the international provider of software and hardware for new mobility services, has launched its first co-developed e-bike. Unveiled at the Wunder Mobility Summit 2021, the new bike has been designed in partnership with Yadea, specifically for shared use. It boasts an industry-topping range of 120km, comes with a speed of 25 km/h, and is specifically designed for European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028006347/en/
Wunder Mobility's new e-bike has been designed in partnership with Yadea, specifically for shared use.
The e-bike’s launch follows the recent IPCC Intergovernmental Panel on Climate Change Sixth Assessment Report which drastically shows that CO2 emissions must be substantially reduced.
As an environmentally friendly mode of transport, bike-sharing is expected to grow 11% worldwide by 2025. During COVID-19, spurred on by booming consumer demand, many city authorities have increased their efforts to make their cities more bike-friendly. Initiatives include pop-up lanes and new cycleways. Political commitments to a transition to the Green Economy continue to drive investment in cycling infrastructure.
Working with Yadea, the world’s largest manufacturer of electric two-wheel vehicles, Wunder Mobility's own e-bike is a leap forward in design to help shared mobility operators capitalise on increasing opportunity. The companies are building on their long-standing relationship with Wunder Mobility’s software integrating with Yadea vehicles since 2019.
Taking shared e-bike performance to the next level
This is the first time an e-bike has been co-designed with Wunder Mobility’s technology and insight at its core. It combines Wunder Mobility’s data-driven understanding of the needs of operators and their users with Yadea’s market leadership in design and manufacturing.
With a range of 120km the e-bike far exceeds the industry average of 70-80km and is based on rider biometrics which best fit the European market. It is equipped with a motor lock and a smart lock for dual security – a rear wheel cover enclosing the locking mechanism to prevent tampering and offering space for marketing purposes. A swappable battery, firmware updates over the air and a built-in IoT connector which comes with Wunder Mobility software provide further ease of use for operators.
Gunnar Froh, Founder and Chief Executive Officer of Wunder Mobility, said:
“Cycling is one of the key solutions for reducing mobility emissions. Through our collaboration we have produced a better performing e-bike for both the operator and the cyclist. This will play a vital role in helping cities and their citizens to achieve green goals and boost wellbeing through exercise. Superior range, weight and security coupled to our powerful platform will enable more short city journeys and cleaner and healthier longer distance urban travel.”
Heidi Zang, Overseas Director at Yadea, said:
“The extensive market research, analysis and design development behind this e-bike has deepened our close collaboration with the team at Wunder Mobility. A market-dominating high range, low weight and uncomplicated maintenance sets new standards and complements the product portfolio of environmentally friendly urban mobility solutions. The simple and smooth design is unique in the sharing field, attracting consumers' attention and encouraging them to choose this e-bike.”
ENDS
Yadea:
Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea's mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.
For more information: www.yadea.com.
Wunder Mobility:
Wunder Mobility is the global leader in software and hardware for new mobility services. The mobility tech company provides white-label solutions that enable enterprises, startups and cities worldwide to deliver sustainable, convenient and secure mobility.
100+ customers in over 900 cities on six continents use the Wunder Mobility platform to launch and scale new mobility services, manage and finance shared vehicle fleets, optimize daily operations, and improve urban planning and traffic management.
The global Wunder Mobility team, with more than 40 nationalities, consists of technology and mobility industry veterans. 50% of the team is in Product and Engineering. Wunder Mobility was founded in 2014 by Gunnar Froh and Sam Baker. The headquarters are in Hamburg, with additional locations in Dortmund and Los Angeles. For more information:
www.wundermobility.com | LinkedIn | Twitter | YouTube | Wunder Mobility Podcast
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006347/en/
Contact information
Press contact
WunderCar Mobility Solutions GmbH
Marius Koch
Mail: press@wundermobility.com
Tel: +49 1515 339 1834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
